Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

A Pragmatic Study of MRD-Guided Maintenance for Multiple Myeloma in Latin America

13 novembre 2026 aggiornato da: David Gomez Almaguer, Hospital Universitario Dr. Jose E. Gonzalez

Applicability of MRD to Tailored Maintenance in Multiple Myeloma: A Pragmatic Prospective Multicenter Study in Latin America

This prospective, pragmatic, multicenter study aims to evaluate the clinical and quality-of-life outcomes of discontinuing maintenance therapy in newly diagnosed MM patients with sustained MRD negativity for two years. By implementing a structured active surveillance strategy with serial MRD and QoL assessments, this study seeks to determine whether treatment-free intervals can be safely achieved without compromising survival outcomes, while improving patient well-being and reducing financial burden.

If successful, this study will provide foundational evidence to support MRD-guided, individualized maintenance strategies in MM and will serve as a platform for future interventional trials in Latin America.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Multiple myeloma is a blood cancer that can require long-term maintenance treatment, even after a very good response to initial therapy. Although maintenance treatment can help control the disease, continuing it for many years may cause side effects, affect quality of life, and create financial burdens. Measurable residual disease (MRD) testing can detect very small amounts of myeloma cells that may remain after treatment.

This prospective, multicenter study in Latin America will evaluate a strategy of stopping maintenance therapy in selected adults with newly diagnosed multiple myeloma who have achieved a complete or stringent complete response and have remained MRD-negative for at least two consecutive years while receiving maintenance therapy.

After maintenance therapy is discontinued, participants will be followed for 24 months through clinical assessments, MRD testing, and quality-of-life questionnaires every six months. Maintenance therapy will be restarted if MRD reappears or if clinical or biochemical criteria for disease relapse are met, according to the study protocol.

The main objective is to evaluate whether this strategy can be implemented safely and to measure the occurrence of MRD reappearance, disease relapse, or death within 24 months. Additional objectives include evaluating progression-free survival, overall survival, quality of life, time until maintenance therapy is restarted, and the feasibility of this approach across Latin American centers.

The study aims to generate evidence to help guide individualized maintenance treatment decisions for selected patients with multiple myeloma.

Tipo di studio

Interventistico

Iscrizione (Stimato)

62

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Age ≥18 years at the time of enrollment.
  • Diagnosis of newly diagnosed multiple myeloma according to International Myeloma Working Group (IMWG) criteria.
  • Achievement of complete response (CR) or stringent complete response (sCR) following first-line therapy, with or without autologous hematopoietic cell transplantation (auto-HCT).
  • Receipt of maintenance therapy for a minimum of 12 months prior to screening.
  • Sustained measurable residual disease (MRD) negativity documented by next-generation flow cytometry (NGF assay EuroFlow-based or equivalent): MRD negativity confirmed on at least two consecutive bone marrow assessments, separated by a minimum of 12 months, with assessments performed during ongoing maintenance therapy.
  • Negative functional imaging prior to maintenance discontinuation, defined as no evidence of metabolically active focal lesions on PET/CT, performed during screening.
  • Absence of extramedullary disease at the time of study entry.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
  • Ability to comply with study procedures, including serial MRD and quality-of-life assessments.
  • Provision of written informed consent prior to any study-specific procedures.

Exclusion Criteria:

  • Evidence of MRD positivity by NGF at any assessment during screening.
  • PET/CT-positive lesions suggestive of active myeloma at screening.
  • Biochemical or clinical relapse at the time of screening, as defined by IMWG criteria.
  • Prior progression while receiving maintenance therapy.
  • Any uncontrolled medical condition or comorbidity that, in the investigator's judgment, would compromise patient safety or protocol compliance.
  • Inability or unwillingness to adhere to protocol-defined follow-up and surveillance procedures.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: MRD-Guided Maintenance Discontinuation and Active Surveillance

Eligible participants will discontinue maintenance therapy after meeting the protocol-defined criteria, including sustained measurable residual disease (MRD) negativity for at least two consecutive years and no evidence of active disease on PET/CT. Participants will undergo active surveillance for 24 months, with clinical assessments, MRD testing, and health-related quality-of-life evaluations every six months. If MRD reappears or clinical or biochemical disease relapse criteria are met, maintenance therapy will be reinitiated according to the study protocol. All participants will receive the same intervention strategy, as this is a single-arm study.

The intervention consists of discontinuing maintenance therapy in selected adults with newly diagnosed multiple myeloma who have achieved complete response or stringent complete response and sustained measurable residual disease (MRD) negativity for at least two consecutive years during maintenance therapy, with no evidence of active disease on PET/CT. Following discontinuation, participants will undergo active surveillance for 24 months, with clinical assessments, bone marrow MRD testing, and health-related quality-of-life evaluations every six months. MRD will be assessed using next-generation flow cytometry. Maintenance therapy will be reinitiated if MRD reappears or if clinical or biochemical disease relapse criteria are met, according to the study protocol. The strategy is evaluated prospectively in a single-arm, multicenter study across Latin America.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Strategy Failure Rate at 24 Months Following MRD-Guided Maintenance Discontinuation
Lasso di tempo: From maintenance discontinuation (baseline) through 24 months.

Strategy failure is defined as the first occurrence of any of the following events after maintenance discontinuation: (1) measurable residual disease (MRD) resurgence, defined as conversion from sustained MRD negativity to MRD positivity detected by next-generation flow cytometry (EuroFlow; sensitivity ≥10^-5); (2) clinical or biochemical relapse/progression according to IMWG criteria; or (3) death from any cause. The outcome will be measured as the proportion of participants experiencing at least one strategy failure event.

From maintenance discontinuation (baseline) through 24 months.

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Measurable Residual Disease-Free Survival (MRD-FS)
Lasso di tempo: From maintenance discontinuation through 24 months.

Time from maintenance discontinuation to the first occurrence of MRD resurgence or death from any cause. MRD will be assessed using next-generation flow cytometry (EuroFlow; sensitivity ≥10^-5). MRD-FS will be estimated using the Kaplan-Meier method.

From maintenance discontinuation through 24 months.
Treatment-Free Survival (TFS)
Lasso di tempo: From maintenance discontinuation through 24 months.

Time from maintenance discontinuation to re-initiation of maintenance therapy or death from any cause, whichever occurs first. TFS will be estimated using the Kaplan-Meier method.

From maintenance discontinuation through 24 months.
Progression-Free Survival (PFS)
Lasso di tempo: From maintenance discontinuation through 24 months.

Time from maintenance discontinuation to documented clinical or biochemical disease progression according to IMWG criteria or death from any cause, whichever occurs first. PFS will be estimated using the Kaplan-Meier method.

From maintenance discontinuation through 24 months.
Overall Survival (OS)
Lasso di tempo: From maintenance discontinuation through 24 months.

Time from maintenance discontinuation to death from any cause. Overall survival will be estimated using the Kaplan-Meier method, with survival probabilities reported at 12 and 24 months.

From maintenance discontinuation through 24 months.
Measurable Residual Disease (MRD) Resurgence Rate
Lasso di tempo: At months 6, 12, 18, and 24 after maintenance discontinuation.

Proportion of participants who convert from sustained MRD negativity to MRD positivity during follow-up, assessed by next-generation flow cytometry (EuroFlow; sensitivity ≥10^-5).

At months 6, 12, 18, and 24 after maintenance discontinuation.
Time to Maintenance Therapy Re-initiation
Lasso di tempo: From maintenance discontinuation through 24 months.

Time from maintenance discontinuation to the re-initiation of maintenance therapy, regardless of whether treatment is restarted due to MRD resurgence, clinical or biochemical relapse, or investigator discretion.

From maintenance discontinuation through 24 months.
Change From Baseline in Health-Related Quality of Life Assessed by EORTC QLQ-C30
Lasso di tempo: Baseline and months 6, 12, 18, and 24.

Changes in health-related quality of life will be assessed using the EORTC QLQ-C30 questionnaire.

Baseline and months 6, 12, 18, and 24.
Change From Baseline in Multiple Myeloma-Specific Quality of Life Assessed by EORTC QLQ-MY20
Lasso di tempo: Baseline and months 6, 12, 18, and 24.

Changes in multiple myeloma-specific health-related quality of life will be assessed using the EORTC QLQ-MY20 questionnaire.

Baseline and months 6, 12, 18, and 24.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 novembre 2026

Completamento primario (Stimato)

30 novembre 2028

Completamento dello studio (Stimato)

30 novembre 2030

Date di iscrizione allo studio

Primo inviato

13 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

13 novembre 2026

Primo Inserito (Effettivo)

19 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

19 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

13 novembre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • HE26-00024

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .